Company: DHR
Filing Date: 2025-02-20
Form Type: 10-K
Source: 0000313616-25-000043
Chunk: 230

Company: DANAHER CORP /DE/
Filing Date: 2025-02-20
Form: 10-K
Item: Item 5
Chunk 230
---
42023 Gross CarryingAmountAccumulatedAmortizationGross CarryingAmountAccumulatedAmortizationFinite-lived intangibles:Patents and technology$14,781 $(4,641)$15,175 $(3,832)Customer relationships, trade names and other intangibles9,972 (4,781)10,131 (4,303)Total finite-lived intangibles24,753 (9,422)25,306 (8,135)Indefinite-lived intangibles:Trademarks and trade names3,237 — 3,575 — Total intangibles$27,990 $(9,422)$28,881 $(8,135)During 2024, the Company acquired finite-lived intangible assets, consisting primarily of developed technology, customer relationships and trade names, with a weighted average life of 11 years.  Refer to Note 2 for information on the intangible assets acquired.The Company reviews identified intangible assets for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable.  Indefinite-lived intangibles are subject to impairment testing at least annually or more frequently if events or changes in circumstances indicate that potential impairment exists.  During the third quarter of 2024, the Company concluded that it had an impairment indicator for an indefinite-lived trade name within the genomics consumable business included in the Life Sciences segment.  This determination was primarily the result of softness in the genomics market, including but not limited to the discontinuation of drug development programs announced in the third quarter and weaker demand at some of the business’s larger customers as well as reduced demand due to the reprioritization of drug development programs at other customers.  The Company engaged a third-party valuation specialist to assist in the valuation of the trade name using a relief from royalty method of valuation.  The significant assumptions in the relief from royalty method include, but were not limited to, revenue growth rates (including perpetual growth rates), royalty rates and discount rates.  The Company recorded a noncash impairment 

79

charge of $222 million pretax ($169 million after-tax) related to the indefinite-lived trade name for the year ended December 31, 2024.  After recognition of the impairment, the net book value of the trade name was $508 million and the Company continues to monitor for any changes to the business performance or key assumptions.  In connection